Stanley L. Hazen, MD, PhD

Stanley L. Hazen, MD, PhD

Founder and Scientific Advisor

Stanley Hazen, MD, PhD, received clinical training in Internal Medicine and subspecialty training in Diabetes, Endocrinology and Metabolism from Barnes/Jewish Hospital, St. Louis, MO, and a PhD in Biophysical Chemistry and Molecular Biology from Washington University School of Medicine, St. Louis, MO. He holds multiple leadership positions at the Cleveland Clinic including chair, Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, co-Section head, Preventive Cardiology & Rehabilitation, Heart, Vascular & Thoracic Institute, and Director, Center for Microbiome & Human Health. Dr. Hazen sees patients within the Preventive Cardiology Clinic, specializing in preventive cardiovascular medicine care of patients including treatment of hyperlipidemia, hypertension, obesity and diabetes. He also sees patients within the Cardiovascular Rehabilitation program. His research interests include studies of mechanisms for the development of cardiovascular disease, with emphasis on understanding the role of the gut microbiome, inflammation and oxidant stress in the pathogenesis of atherosclerosis and other inflammatory diseases.

A renowned physician scientist, Dr. Hazen has made pioneering discoveries in new understandings of mechanisms contributing to cardiovascular and inflammatory disease research. He is credited with numerous seminal discoveries linking gut microbial pathways to cardiovascular disease pathogenesis, as well as enumerating the role of myeloperoxidase and other inflammatory and oxidative pathways in cardiovascular disease. Dr. Hazen is among the top 0.1% cited researchers in the world with over 140,000 citations. He has published over 475 peer-reviewed articles in top tier basic and clinical journals alike in the fields of atherosclerosis, lipoprotein metabolism, gut microbiome, inflammation, vascular biology, and other topics related to preventive cardiovascular medicine. His research in multiple areas has impacted clinical practice, and lays the foundation for FDA- and EU-cleared diagnostic tests for cardiovascular disease risk assessment in use worldwide. He is listed as inventor on over 100 patents, and his research has helped to spawn pharmaceutical development of cardiovascular disease drugs in clinical trials.

Dr. Hazen has received numerous awards including being the Inaugural recipient of the Top 10 Clinical Discovery of the Year (2011) Award, Clinical Research Forum; the American Heart Association/American Stroke Association “top 10 advance in heart disease and stroke science” award (2013); and the American Heart Association Distinguished Scientist Award (2017). Dr Hazen has been honored with election of membership into honorary societies in both science and clinical arenas alike, including the American Society for Clinical Investigation (ASCI) and the American Association of Physicians (AAP). Dr. Hazen is an elected fellow of the American Association for the Advancement of Science (AAAS). Dr. Hazen also is an elected member of the National Academy of Medicine, USA.

Previous Experience: